Establishment Labs Surpasses Three Million Motiva Devices

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has achieved a significant milestone by surpassing three million Motiva® devices sold globally, with less than 1% device-related complications reported over 12 years. This reflects the company's commitment to advancing women's health and wellness in breast aesthetics and reconstruction. CEO Juan José Chacón-Quirós highlighted their innovation-driven approach, while Dr. Heather Brennan emphasized the upcoming Sulàyöm Campus that will more than double manufacturing capacity. The company continues to prioritize safety and clinical performance, supported by extensive research and patent filings.

Positive

• Surpassed three million Motiva® devices sold globally.
• Reported less than 1% device-related complication rates over 12+ years.
• New Sulàyöm Campus to open in July, doubling manufacturing capacity.

Negative

• Motiva Implants® are currently not approved for sale in the United States.

• Less than 1% device-related complication rates reported in post market surveillance data over 12+ years.

NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva^® devices in market.

“Since its founding, Establishment Labs has been guided by one core principle: putting women at the center of everything we do,” said Juan José Chacón-Quirós, Establishment Labs CEO and Founder. “We let science, engineering, and evidence drive our research and development, and this is reflected in the outstanding performance of our portfolio of solutions for breast aesthetics and reconstruction. By leading with innovation for over twelve years now, we have transformed the future of this industry.”

“The superior performance of Motiva is seen in our internal registries and warranty claims, as well as from independent registries and peer-reviewed publications, all of which are referenced in our annual Post Market Surveillance report,” said Dr. Heather Brennan, General Manager, Global Markets. “Our expectations for continued growth are clear: with our new Sulàyöm Campus, which is opening in July, we are more than doubling our manufacturing capacity to address the growing demand for Motiva. We believe that by setting new standards in safety and clinical performance, we will expand markets in breast aesthetics and reconstruction.”

Establishment Labs’ 2022 Post Market Surveillance Report is available at: Motiva PMS Report. Motiva Implants are undergoing an IDE clinical trial and are not approved for sale in the United States.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is the only regulatory-approved expander in the world with an integrated port that is MRI conditional and is used to improve outcomes in breast reconstruction following breast cancer. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. In 2018, the Company received an investigational device exemption (IDE) from the FDA for Motiva Implants® and began a clinical trial to support regulatory approval in the United States. Please visit our website for additional information at establishmentlabs.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company’s quarterly report and annual reports, and other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005359/en/

Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

What milestone did Establishment Labs announce regarding Motiva devices?

Establishment Labs announced it has surpassed three million Motiva® devices sold globally.

What complication rates were reported by Establishment Labs?

Establishment Labs reported less than 1% device-related complications over 12+ years.

When is the new Sulàyöm Campus expected to open?

The new Sulàyöm Campus is expected to open in July.

Is Motiva Implants® approved for sale in the United States?

No, Motiva Implants® are currently not approved for sale in the United States.